Immune Half-life extended trispecific anti-peanut antibody provides continuous protection from allergic reactions March 10, 2025 Mabylon AG recently provided preclinical data for MY-006, a half-life extended trispecific anti-peanut antibody being developed for the treatment of peanut allergy.Read More